OR WAIT null SECS
The facility will include a high-speed sterile line for live virus filling, a line for standard fill/finish, cleanroom capacity, labs, warehousing, and offices to support production.
Thermo Fisher Scientific announced on Oct. 14, 2020 that it is developing two new sterile filling lines in Singapore for the development and manufacturing of therapies and vaccines for the Asia-Pacific region.
The new $130 million facility will be operated by Thermo Fisher who will ensure the site has the ability to manufacture pharmaceutical products to meet demand and respond to health emergencies, a company press release said. The facility will include a high-speed sterile line for live virus filling, a line for standard fill/finish, cleanroom capacity, labs, warehousing, and offices to support production.
The site will be operational in 2022 and will have the potential to manufacture up to 30 million sterile doses per month and house more than 300 employees, the press release said.
"The COVID-19 pandemic has shown us the importance of government and industry collaboration to protect citizens by ensuring the availability of critical diagnostic tests, therapies, and vaccines," said Marc N. Casper, chairman, CEO, and president of Thermo Fisher Scientific, in the press release. "This partnership enables us to expand our sterile fill finish network in the region while strengthening the Singapore government's ability to respond quickly to future health crises."
Source: Thermo Fisher Scientific